



(86) Date de dépôt PCT/PCT Filing Date: 2005/03/18
 (87) Date publication PCT/PCT Publication Date: 2005/09/22
 (45) Date de délivrance/Issue Date: 2011/09/06
 (85) Entrée phase nationale/National Entry: 2006/09/13
 (86) N° demande PCT/PCT Application No.: CU 2005/000002
 (87) N° publication PCT/PCT Publication No.: 2005/087259
 (30) Priorité/Priority: 2004/03/18 (CU2004-0051)

(51) Cl.Int./Int.Cl. *A61K 39/00* (2006.01),
A61K 39/04 (2006.01), *A61P 15/00* (2006.01),
A61P 35/00 (2006.01), *A61P 37/00* (2006.01)
 (72) Inventeurs/Inventors:
 SARMIENTO GARCIA SAN MIGUEL, MARIA ELENA,
 CU;
 ACOSTA DOMINGUEZ, ARMANDO, CU;
 VALLIN PLOUS, CARLOS ROMAN, CU;
 OLIVARES ARZUAGA, NESTY, CU;
 LOPEZ HERNANDEZ, YAMILE, CU;
 ...
 (73) Propriétaires/Owners:

(54) Titre : COMPOSITIONS DE VACCIN OBTENUES A PARTIR DE STREPTOMYCES
 (54) Title: VACCINE COMPOSITIONS OBTAINED FROM STREPTOMYCES

(57) **Abrégé/Abstract:**

The invention relates to the field of immunology and, more specifically, to the control of infectious diseases caused by microbacteria, which is based on the use of vaccines for the prevention of said diseases. The inventive vaccines have been developed with the use of live strains of Streptomyces, which may or may not express antigens of M. tuberculosis, and have demonstrated their protective capacity against the threat of BCG and M. tuberculosis after being administered by different routes. The invention also relates to the use of strains of Streptomyces for the expression of heterologous antigens of vaccinal interest.

(72) **Inventeurs(suite)/Inventors(continued):** RODRIGUEZ VALDES, CARIDAD, CU; MARTINEZ BENITEZ, MAXIMO, CU; GONZALEZ MESA, LEONORA, CU; INFANTE BOURZAC, JUAN FRANCISCO, CU; RAMOS MORI, ASTRID, CU

(73) **Propriétaires(suite)/Owners(continued):**
INSTITUTO FINLAY - CENTRO DE INVESTIGACION PRODUCCION DE VACUNAS Y SUEROS, CU;
CENTRO DE QUIMICA FARMACEUTICA, CU

(74) **Agent:** MACRAE & CO.

(12) SOLICITUD INTERNACIONAL PUBLICADA EN VIRTUD DEL TRATADO DE COOPERACIÓN EN MATERIA DE PATENTES (PCT)

(19) Organización Mundial de la Propiedad
Intelectual
Oficina internacional(43) Fecha de publicación internacional
22 de Septiembre de 2005 (22.09.2005)

PCT

(10) Número de Publicación Internacional
WO 2005/087259 A1(51) Clasificación Internacional de Patentes⁷: **A61K 39/00**,
39/04, A61P 37/00, 35/00, 15/00(21) Número de la solicitud internacional:
PCT/CU2005/000002(22) Fecha de presentación internacional:
18 de Marzo de 2005 (18.03.2005)

(25) Idioma de presentación: español

(26) Idioma de publicación: español

(30) Datos relativos a la prioridad:
2004-0051 18 de Marzo de 2004 (18.03.2004) CU(71) Solicitantes (para todos los Estados designados salvo US): **INSTITUTO FINLAY - CENTRO DE INVESTIGACIÓN PRODUCCIÓN DE VACUNAS Y SUEROS** [CU/CU]; Ave 27 No 19805 e/ 198 y 202 La Coronela - La Lisa, 11000 Ciudad de La Habana (CU). **CENTRO DE QUÍMICA FARMACEUTICA.** [CU/CU]; Ave 200 y 2 - Atabey, Cubanacán- Playa, 11200 Ciudad de La Habana (CU).

(72) Inventores; e

(75) Inventores/Solicitantes (para US solamente): **SARMIENTO GARCÍA SAN MIGUEL, María, Elena** [CU/CU]; Ave 1ra, No. 1207 Apto 2. e/ 12 y 14 Miramar - Playa, 11300 Ciudad de La Habana (CU). **ACOSTA DOMINGUEZ, Armando** [CU/CU]; Ave 1ra, No. 1207 Apto 2. e/ 12 y 14 Miramar - Playa, 11300 Ciudad de La Habana (CU). **VALLIN PLOUS, Carlos, Román** [CU/CU]; Calle 170, BCE-3 Apto 4, e/ 1ra y 5ta Reparto Flores - Playa, 11200 Ciudad de La Habana (CU). **OLIVARES ARZUAGA, Nesty** [CU/CU]; CalleMartínez No 271 e/ D y E Lawton - 10 de Octubre, 10700 Ciudad de La Habana (CU). **LÓPEZ HERNÁNDEZ, Yamilé** [CU/CU]; Ave 156 No 6920, e/ 69 y 71, La Lisa, 11000 Ciudad de La Habana (CU). **RODRÍGUEZ VALDES, Caridad** [CU/CU]; Calle Chaple No 764, Apto 1 e/ Vía Blanca y Sta Lutgarda, Palatino - Cerro, 12000 Ciudad de La Habana (CU). **MARTÍNEZ BENÍTEZ, Máximo** [CU/CU]; Ave 5ta No 18408, e/ 184 y 186, Playa, 11200 Ciudad de La Habana (CU). **GONZÁLEZ MESA, Leonora** [CU/CU]; Ave 57 No 13607, e/ 136 y 138, Marianao, 11500 Ciudad de La Habana (CU). **INFANTE BOURZAC, Juan, Francisco** [CU/CU]; Ave 29, No 3604 e/ 36 y 42, Playa, 11200 Ciudad de La Habana (CU). **RAMOS MORI, Astrid** [CU/CU]; Zona 12, Edif. H-15, Apto 9 Alamar, Habana del Este, 11900 Ciudad de La Habana (CU).(74) Mandatario: **VAZQUEZ D'ALVARE, Danice**; Ave 1ra, No 1001 Esq. a 10, Miramar - Playa, 11300 Ciudad de La Habana (CU).

(81) Estados designados (a menos que se indique otra cosa, para toda clase de protección nacional admisible): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Estados designados (a menos que se indique otra cosa, para toda clase de protección regional admisible): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), euroasiática (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), europea (AT, BE, BG, CH, CY, CZ, DE, DK,

[Continúa en la página siguiente]

(54) Title: VACCINE COMPOSITIONS WHICH ARE OBTAINED FROM STREPTOMYCES

(54) Título: COMPOSICIONES VACUNALES OBTENIDAS A PARTIR DE STREPTOMYCES.

(57) Abstract: The invention relates to the field of immunology and, more specifically, to the control of infectious diseases caused by microbacteria, which is based on the use of vaccines for the prevention of said diseases. The inventive vaccines have been developed with the use of live strains of Streptomyces, which may or may not express antigens of *M. tuberculosis*, and have demonstrated their protective capacity against the threat of BCG and *M. tuberculosis* after being administered by different routes. The invention also relates to the use of strains of Streptomyces for the expression of heterologous antigens of vaccinal interest.(57) Resumen: La presente invención se relaciona con el campo de la inmunología, específicamente con el control de enfermedades infecciosas causadas por micobacterias, basado en el uso de vacunas para la prevención de estas enfermedades. Con la presente invención se desarrollaron vacunas basadas en el uso de cepas vivas de Streptomyces expresando o no antígenos de *M. tuberculosis*, las cuales demostraron su capacidad protectora frente al reto con BCG y *M. tuberculosis* después de ser administradas por distintas vías. Forma parte de la presente invención el uso de cepas de Streptomyces para la expresión de antígenos heterólogos de interés vacunal.

WO 2005/087259 A1

WO 2005/087259 A1



EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL,
PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI,
CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

— *antes de la expiración del plazo para modificar las reivin-
dicaciones y para ser republicada si se reciben modifica-
ciones*

Publicada:

— *con informe de búsqueda internacional*

*Para códigos de dos letras y otras abreviaturas, véase la sección
"Guidance Notes on Codes and Abbreviations" que aparece al
principio de cada número regular de la Gaceta del PCT.*

VACCINE COMPOSITIONS OBTAINED FROM STREPTOMYCES.

The present invention relates to the field of immunology, specifically to the control of infectious diseases caused by mycobacteria using vaccines developed from live strains of *Streptomyces*, expressing or not antigens of *M. tuberculosis*, which demonstrated their protective capacity against challenge with BCG and *M. tuberculosis* after being administered by different routes.

Among mycobacteria, important pathogens for animals and men are found: *Mycobacterium tuberculosis* which causes tuberculosis, *Mycobacterium leprae* responsible for leprosy, *Mycobacterium avium* and *Mycobacterium intracelulare* which cause tuberculosis in immunodepressed patients as well as other mycobacteria which cause diseases in humans, although to a lesser degree (Somner HM, Good RC. *Mycobacterium*. In: Manual of clinical Microbiology, 4 ed. Washington D.C: A Society for Microbiology; 1985. p.216-248., Orme IM. Immunity to mycobacteria. Current Opinion in Immunology. 1993; 5: 497-502).

In the case of animals, *Mycobacterium avium* subsp. *pararatuberculosis* causing Jones Disease in ruminants and *Mycobacterium bovis* causing tuberculosis in cattle highlight. (Dannenbergh Am. Pathogenesis of tuberculosis: native and acquired resistance in animals and humans. In Leive L, Schelesinger D (eds). Microbiology. 1984, p344-354).

Tuberculosis (TB) is among the most important mycobacterial diseases in men. It constitutes a world health problem and it is the leading cause of death associated to infectious diseases despite vaccination with BCG and the use of a great number of drugs for its control (Dolin PJ, Raviglione MK, Kochi A. Global tuberculosis incidence and mortality during 1990-2000. Bull WHO. 2001; 72: 213).

It is estimated that the third part of the world population has been infected by *Mycobacterium tuberculosis*. All over the world, eight million people develop active TB every year and three million dies. Co-infection with the Human Immunodeficiency Virus (HIV) represents 3 to 5 % of the cases (Dolin PJ, Raviglione MK, Kochi A. Global tuberculosis incidence and mortality during 1990-2000. Bull WHO. 1994; 72: 213).

Due to the great spread of the disease, new and better diagnosis methods, vaccine preparations and therapeutical agents are required (Collins FM. Tuberculosis: The Return of an Old Enemy. *Critical Reviews in Microbiology*. 1993; 19: 1-16).

Treatment is based on drugs combinations administered in relatively high doses for long periods of time with associated toxicity. This makes difficult the implementation of programs of controlled treatment (McCarthy M. Experts see progress in fight against tuberculosis *Lancet*. 2002; 359:2005). In this regard, the decrease of treatment times favoring the application of control programs and their fulfillment that would avoid the appearance of resistant strains, is desirable. Decreasing doses of pharmaceuticals used would also be a useful element to diminish the treatment toxicity.

Currently, the appearance of strains with multiple resistance to drugs is an increasing problem which claims the development of new therapeutical alternatives for the high number of infected individuals (50 millions) and for the increasing number of patients with these characteristics occurring in the future (McCarthy M, News. Experts see progress in fight against tuberculosis. *Lancet*. 2002; 359:2005; Hopewell PC. Tuberculosis Control: How the world has changed since 1990. *Bull. World Health Org* 2002, 80:427, Freire M, Rosigno G Joining forces to develop weapons against TB: together we must. *Bull. World Health Org* 2002, 80:429).

Additionally, there exist multiple species of mycobacteria causing diseases in man for which an adequate treatment is not available.

BCG is the only tuberculosis vaccine currently available for human use. Almost three billion doses have been applied all over the world. Its efficacy widely varies depending on the strain used, nutritional status, genetic background, aging and presence of intercurrent infections. Its use is considered only effective to prevent the serious forms of the disease (miliary and meningitis) in infancy but not to prevent pulmonary tuberculosis; so it is urgent to develop new vaccine preparations (Hirsch LS, Johnson-JL, Ellner JJ. Pulmonary tuberculosis. *Curr-Opin-Pulm-Med*1999;5(3):143-50; Jacobs GG, Johnson JL, Wallis RS. Tuberculosis vaccines: how close to human testing. *Tuber Lung Dis* 1997;78:159-169; Ginsberg AM. What's new in tuberculosis vaccines? *Bull. World Health Org* 2002, 80:483).

The most important strategies to develop vaccines against tuberculosis include the use of inactivated strains, genetically or not attenuated strains, nucleic acids vaccines, subunits vaccines and attenuated live strains expressing antigens of *M. tuberculosis*.

Since inactivated vaccines are composed of dead microorganisms, they present the disadvantage of having a decreased protective capacity due to the impossibility of persistence in vivo and to produce relevant proteins for protection as the secreted ones.

The attenuated strains present as disadvantage the possibility of reversion to virulence after being administered which is of concern with regard to safety of humans.

Nucleic acids vaccines, despite being a promising strategy so far, have not achieved adequate immunogenicity levels in humans.

Sub-units vaccines are considered not to have the same immunogenicity potential as live microorganisms because they are purified components from the microorganism or obtained by recombinant methods which makes difficult to achieve protective responses, mainly cell responses of T-cell type, T-helper type 1 (TH 1).

The strategy of antigen expression of vaccine interest in attenuated live strains is one of the most promising strategies in the field of new generation vaccines against tuberculosis.

An important element of this strategy is the selection of the expression vector, which depending on the selected strain, could have complications from the regulatory point of view, similar to those faced with the use of attenuated live strains.

Taking into account that *Streptomyces* and *M. tuberculosis* belong to the same class and share a great quantity of genes and antigens together with the proven innocuity of *Streptomyces* for men, the wide use of these bacteria to produce pharmaceuticals for human use as well as the big development of methods for the expression of heterologous proteins in this system, including proteins of *M. tuberculosis*, the development of vaccines against tuberculosis using as active principles live strains of *Streptomyces* that can express or not antigens of *M. tuberculosis* administered by different routes, including the mucosal, was designed by the present invention.

The vaccine preparations of the present invention comprise a variety of active principles derived from the microorganism *Streptomyces*. Among them, we have:

Streptomyces (wild strain)

Recombinant *Streptomyces* expressing the antigen Apa of *M. tuberculosis*

The wild strain used in the present invention is a non-pathogenic industrial strain, widely used in the production of medicines for man.

A marked humoral and cellular immunogenicity of strains after their administration by different routes was surprisingly observed. The responses obtained were directed against the antigens of the strain used in the immunization (*Streptomyces*), against the antigen of *M. tuberculosis* expressed (Apa) and against other antigens of *M. tuberculosis* and BCG (Example 1), which confirmed the antigen community existing between *Streptomyces* and Mycobacteria and their wide cross-reactivity. This fact guaranteed the use of these strains as vaccines against *M. tuberculosis*.

Another fact guaranteeing their use is their incapability to colonize and cause histopathological lesions in hosts, which reaffirms their innocuity (Example 2)

These strains are prophylactically applicable to prevent tuberculosis. Induction of a protective condition against *M. tuberculosis* and BCG was shown in all the administration routes used (Example 3).

The compositions of the present invention produced a significant decrease in the levels of pulmonary infection with BCG and *M. tuberculosis* in an infection model in mice (Example 3).

The present invention approaches in a novel way the prevention of diseases caused by mycobacteria, in particular against tuberculosis, using vaccines based on *Streptomyces* strains. It is particularly novel the use of *Streptomyces* strains, not known at all in the state-of-the-art. It is also novel the fact that these strains were effective both by mucosal and parenteral route.

It was significant the fact that the *Streptomyces* strains can be used as live vectors of antigen expression of vaccine interest that has not been reported in the state-of the art. This has broadened the possibility to use these strains for the expression on non-mycobacterial antigens allowing their use to prevent and treat allergic, tumoral and autoimmune diseases and to prevent pregnancy.

The present invention will be described through the following specific examples:

Example 1. Immunogenicity study**Animals:**

Male, 8-10 weeks old Balb/c mice supplied by CENPALAB, Cuba, were used in the experiments.

BCG

Lyophilized, live attenuated BCG. InterVax, Biological Limited, Canada.

Streptomyces lividans

Strain 1326, untransformed and transformed genetically expressing the ApA protein of *Mycobacterium tuberculosis* were used in the experiments.

Immunization schedule

30 Balb/c mice were divided into 4 groups of 10 animals each. (Table 1).

Animals from the group 2 received 3 doses of 10^5 CFU of *S. lividans* IP at 3 week intervals. The animals of the group 3 received *S. lividans* expressing the ApA protein of *M. tuberculosis*.

The animals of group 4 were immunized with the same schedule but using 10^5 of BCG in each immunization.

Group 1 received SS and was used as control.

21 days after the last immunization blood samples were taken from each animal.

Table 1: Immunogenicity study

GROUP	ROUTE	INOCULUM	N
1 (negative control)	IP	SSF 200 μ L	10
2		<i>Streptomyces lividans</i> 10^5 CFU	10
3		BCG 10^5 CFU	10

Western Blot

Protein extracts of *S. lividans* and BCG and recombinant Apa protein of *M. tuberculosis* were separated by SDS-PAGE (Laemmli A, UK. Nature 1970; 227(6): 680-685) and blotted to a 0.45 mcm nitrocellulose membrane using a semi-dry system (NovaBlot II, Pharmacia, Sweeden).

The membranes were blocked with BSA, 2% in PBS for 2 hours at 37, washed and incubated for 1 hour at 37 with polls of sera of the animals of groups 2, 3 and 4 diluted 1.150 in PBS.

After the wash, the membranes were incubated with a polyvalent anti mouse peroxidase conjugate (Sigma), diluted 1.1500 for 1 hour at 37 and developed with Diaminobenzidine and H₂O₂ as substrate.

The result obtained from the immunogenicity study demonstrated the induction of specific antibody responses against the antigens of *S. lividans* in the animals immunized with the microorganism (**Figure 1**).

Additionally, the immunized animals recognized proteins of BCG, demonstrating the cross reactivity with mycobacteria of the immune response elicited (**Figure 1**). This result s highly relevant, demonstrating the immunizing potential of *Streptomyces* against mycobacteria. The cross reactivity against *Streptomyces* of the response elicited against BCG was too demonstrated (**Figure 2**). The animals sera immunized with Saline Solution were not reactive against antigens of *Streptomyces* or BCG (**Figure 3**).

The group of animals immunized with *Streptomyces* expressing the Apa protein of *M. tuberculosis* showed a similar response than the animals immunized with the non transformed *Streptomyces* (data non shown). In this group of animals an specific immune response was demonstrated against the Apa protein by Western Blot (data non shown). This result demonstrated the capability of *Streptomyces* to be used as live vector for the expression of heterologous antigens, in particular from *M. tuberculosis*.

Example 2. Biodistribution study

Animals:

Male, 8-10 weeks old Balb/c mice supplied by CENPALAB, Cuba, were used in the experiments.

BCG

Lyophilized, live attenuated BCG. InterVax, Biological Limited, Canada.

Streptomyces lividans

Strain 1326, untransformed and transformed genetically expressing the ApA protein of *Mycobacterium tuberculosis* were used in the experiments.

The study was designed with 48 mice, distributed in 8 groups of 6 animals (Table 2)

Animals from the groups 2, 3 and 4 received *S. lividans* in doses of 10^5 , 10^3 and 10^2 respectively in 200 μ l of distilled water by the intraperitoneal route (IP).

The animals from the groups 6, 7 and 8 received *S. lividans* in doses of 10^3 , 10^2 and 10^1 in 50 μ l of distilled water by the intranasal route (IN).

The animals of the group received 200 μ l of Saline Solution (0.9 % NaCl) (SS) IP and the animals of group 5 received 50 μ l of Saline Solution IN.

After 30 days the animals were sacrificed and the heart, lung, liver. Spleen and kidney were studied microbiologically (3 animals) and histopathologically (3 animals).

The histopathological study was made with tissue samples stained with Haematoxylin and Eosin.

The microbiological studies were carried out with YEME medium (Tobias Kieser, Mervyn J. Viv., Mark J. Buttner, Perth F. Charter, David A. Hopwood. Practical *Sytreptomyces* Genetics. Crowes, Norwich. England. 2000).

Tabla 2: Biodistribution of *Streptomyces lividans* in Balb/c mice

GROUP	ROUTE	DOSE	ORGAN
1 (negative control)	IP	SSF 200 μ L	Heart Lung Liver Spleen Kidney
2		10^5 CFU	
3		10^3 CFU	
4		10^2 CFU	
5 (negative control)	IN	SSF 50 μ L	
6		10^3 CFU	
7		10^2 CFU	
8		10^1 CFU	

In the biodistribution study the presence of the microorganism was not evident in the organs studied.

The histopathological study did not demonstrate lesions in the organs studied. Similar results were obtained in the study of *Streptomyces* expressing the Apa protein of *M. tuberculosis* (data non shown).

Taking into consideration these results, we can conclude that *Streptomyces* is safe, demonstrating the feasibility of their use as live vaccine without adverse effects.

It is important to highlight the fact that despite the safety of the tested strains, they elicited a good immune response (**Figure 1**).

Example 3. Challenge experiments

Animals:

Male, 8-10 weeks old Balb/c mice supplied by CENPALAB, Cuba, were used in the experiments.

BCG

Lyophilized, live attenuated BCG, . InterVax, Biological Limited, Canada.

Streptomyces lividans

Strain 1326, untransformed and transformed genetically expressing the ApA protein of *Mycobacterium tuberculosis* were used in the experiments.

Where studied 26 animals distributed in 3 groups. (Table 3).

The animals were immunized IP 3 times at 2 week intervals. Group 1 with SS, Group 2 with 10^5 CFU of *S. lividans* and Group 3 with 10^5 CFU of BCG.

3 weeks after the last immunization the animals were challenged with 0.5×10^6 CFU of BCG by the IN route. 24 hours later, the animals were sacrificed and the lungs obtained for microbiological studies.

Microbiological studies.

Lung macerates where plated in Ogawa medium (Manual de la OXID. Cuarta Edición. 1981 Editado por OXID Limited, England) and incubated for 28 days at 37. After the incubation period, the CFU were counted and the CFU number/ mg of lung tissue were determined.

Statistical processing

The statistical comparison between groups was made with the Kruskal-Wallis test and the Test of multiple comparisons of free distribution was used as complementary test.

Table 3: Challenge experiment

GROUP	INOCULUM AT 0, 21 Y 42 DAYS	CHALLENGE DAY 63	N
1 (negative control)	SSF 200 μ L	BCG $0,5 \times 10^6$ CFU	8
2	<i>Streptomyces lividans</i> 10^5 CFU		10
3	BCG 10^5 CFU		8

In the group immunized with *Streptomyces* there was a statistical decrease in the CFU of BCG in lungs compared with the animals immunized with BCG and the control group

(Figure 4). Similar results were obtained in the group immunized with *Streptomyces* expressing the Apa protein of *M. tuberculosis* (data non shown).

Groups of animals immunized with transformed and non transformed *Streptomyces* were protected upon challenge with *M. tuberculosis* (data non shown).

The above results demonstrated the protective capacity of *Streptomyces* against mycobacteria and support their use as vaccines for the prevention of mycobacterial infections.

Advantages of the proposed solution.

The advantage of using this kind of strains as vaccines against mycobacterial infections, specially against tuberculosis, is the use of non-pathogenic strains allowing the use of live strains in humans, which guarantees an adequate immunogenicity and stimulation of immune responses for protection.

Another advantage lies in the wide experience in the industrial use of these strains to produce medicines for human use, guaranteeing the industrial production of these vaccines.

The wide knowledge of the genetics of *Streptomyces* and the availability of genetic methods for their transformation and expression of high levels of heterologous antigens are additional advantages for their use as recombinant live attenuated vectors.

The mucosal administration route ensures an easy and versatile application way at the entrance site of mycobacteria favoring the blocking of infection and therefore the prophylactic effect.

The wide cross protective capacity, demonstrated against BCG and *M. tuberculosis* is an important advantage for their use as vaccine against several mycobacterial infections.

The genetically transformed *Streptomyces* strains, expressing antigens of non-mycobacterial vaccine interest, can be used for the prophylaxis or therapeutics of non-mycobacterial infectious, autoimmune, allergic and tumoral diseases and prevention of pregnancy.

Brief description of Figures

Figure 1: Western blot. Nitrocellulose strips with extracts of *S. lividans* (1) and BCG(2) were studied against a pool of sera of animals immunized with *S. lividans* (Group 2)

Figure 2: Western blot. Nitrocellulose strips with extracts of BCG (1) and *S. lividans* (2) were studied against a pool of sera of animals immunized with BCG (Group 3)

Figure 3: Western blot. Nitrocellulose strips with extracts of BCG (1) and *S. lividans* (2) were studied against a pool of sera of animals immunized with Saline Solution (Group 1)

Figure 4: Challenge experiment with BCG. The values represent the mean log of the CFU/mg of lung tissue. There were statistical differences ($p < 0.05$) between the group immunized with Streptomyces (*S. lividans*) and the control group immunized with Saline Solution (CN).

CLAIMS:

1. A vaccine composition obtained from *Streptomyces* characterized in that said composition has as active principle one or more wild strains of *Streptomyces* genus or mutant or recombinant strains derived from such strains and an adequate excipient.
2. The vaccine composition according to claim 1 characterized in that the *Streptomyces* strains are live strains.
3. The vaccine composition according to claim 1 or 2 characterized in that the strains of *Streptomyces* are selected from *Streptomyces lividans*, *Streptomyces coelicolor* and *Streptomyces Sp.*
4. The vaccine composition according to claim 1 characterized in that the recombinant strains of *Streptomyces* express one or more heterologous antigens.
5. The vaccine composition according to claim 4 characterized in that the recombinant strains of *Streptomyces* express one or more heterologous antigens of *Mycobacterium*.
6. Use of the vaccine composition of any one of claims 1 to 5 for the prevention or treatment of infectious diseases.
7. Use, according to claim 6, for the prevention or treatment of an infection caused by *mycobacteria*.
8. Use, according to claim 7, for the prevention or treatment of tuberculosis.
9. Use of the vaccine composition of any one of claims 1 to 5 for the prevention or treatment of tumoral diseases.

10. Use of the vaccine composition of any one of claims 1 to 5 for the prevention or treatment of auto-immune diseases.

11. Use of the vaccine composition of any one of claims 1 to 5 for the prevention or treatment of allergic diseases.

12. Use of the vaccine composition of any one of claims 1 to 5 for the prevention of pregnancy.

Application number: numéro de demande: CU05 00002

Figures: 1 to 3

Pages: _____

DRW-IP

Unscannable items
received with this application
(Request original documents in File Prep. Section on the 10th Floor)

Documents reçus avec cette demande ne pouvant être balayés
(Commander les documents originaux dans la section de préparation des dossiers au
10ième étage)

Figure 4

